This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Mark H. Eckman, MD; Stephen G. Pauker, MD
Boston, Mass

Arch Intern Med. 1995;155(1):115-116.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Hirsh and Poller¹ have examined a number of potential problems that may affect the reliability of the prothrombin time ratio and the international normalized ratio by highlighting sources of variability in the prothrombin time ratio and explaining how some of these are lessened by using the international normalized ratio. However, their article does not adequately emphasize the clinical impact that these inaccuracies have on patient care. The major concern in monitoring the intensity of anticoagulation therapy is how variability in either the prothrombin time ratio or the international normalized ratio affect the likelihood of adverse outcomes, bleeding and thromboemboli. Clinicians must separate variation in their patients' level of anticoagulation from variability introduced in the laboratory. By not accounting for variability in the sensitivity of thromboplastins to the depletion of the vitamin K—dependent coagulation factors, the prothrombin time ratio alone introduces needless uncertainty in the true level of anticoagulation intensity. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?